98%
921
2 minutes
20
Kinase inhibitors are widely used in antitumor research, but there are still many problems such as drug resistance and off-target toxicity. A more suitable solution is to design a multitarget inhibitor with certain selectivity. Herein, computational and experimental studies were applied to the discovery of dual inhibitors against FGFR4 and EGFR. A quantitative structure-property relationship (QSPR) study was carried out to predict the FGFR4 and EGFR activity of a data set consisting of 843 and 5088 compounds, respectively. Four different machine learning methods including support vector machine (SVM), random forest (RF), gradient boost regression tree (GBRT), and XGBoost (XGB) were built using the most suitable features selected by the mutual information algorithm. As for FGFR4 and EGFR, SVM showed the best performance with = 0.80 and = 0.75, demonstrating excellent model stability, which was used to predict the activity of some compounds from an in-house database. Finally, compound was selected, which exhibits inhibitory activity against FGFR4 (IC = 86.2 nM) and EGFR (IC = 83.9 nM) kinase, respectively. Furthermore, molecular docking and molecular dynamics simulations were performed to identify key amino acids for the interaction of compound with FGFR4 and EGFR. In this paper, the machine-learning-based QSAR models were established and effectively applied to the discovery of dual-target inhibitors against FGFR4 and EGFR, demonstrating the great potential of machine learning strategies in dual inhibitor discovery.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.jcim.0c00652 | DOI Listing |
ESMO Open
August 2025
Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.
Background: Despite the clinical impact of breast cancer (BC) brain metastases (BMs), their biological complexity remains poorly understood. We evaluated the genomic profile of BCBMs and compared it with paired primary BC samples to characterize biological changes during brain metastasization and their clinical impact in a retrospective real-world cohort.
Materials And Methods: Expression of 758 genes (BC360 Panel, nCounter), hormone receptor (HR) status, and human epidermal growth factor receptor type 2 (HER2) status were evaluated in BCBMs and matched primary BCs.
Explor Target Antitumor Ther
July 2025
Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, 197758 St.-Petersburg, Russia.
Aim: This study aimed at the identification of new druggable alterations in non-small cell lung carcinomas (NSCLCs).
Methods: RNA next generation sequencing (NGS) analysis for 650 protein kinase genes was performed for 89 NSCLCs obtained from young-onset and/or female non-smokers, who were negative for activating events involving , , , , , , , , , or genes.
Results: RNA sequencing identified 32 in-frame rearrangements, including 9 instances of fully preserved and 8 tumors with partially preserved tyrosine kinase domains.
Clin Cancer Res
September 2025
UT Southwestern Simmons Comprehensive Cancer Center, Dallas, Texas.
Purpose: We report herein a phase Ib trial to determine the safety, tolerability, and antitumor activity of erdafitinib, a pan-FGFR tyrosine kinase inhibitor, with fulvestrant and palbociclib in patients with hormone receptor-positive/HER2-negative metastatic breast cancers (NCT03238196).
Patients And Methods: Thirteen patients were enrolled on the escalation phase in a traditional 3 + 3 trial design to determine the maximum tolerated dose (MTD). Subsequently, 22 patients were treated at the established MTD during the expansion phase.
Discov Oncol
March 2025
Department of Clinical and Administrative Pharmacy Sciences, Howard University, 2400 Sixth Street NW, Washington, DC, 20059, USA.
Background: Colorectal cancer (CRC) is the second most common cancer in men and third in females, a heterogeneous disease involving multistep mechanisms that represents 10% of all cancers globally. This study investigates gene mutation profiling in CRC using Next-Generation sequencing machine.
Method: Formalin-fixed paraffin-embedded tissues of 30 CRC patients were retrieved and reviewed.
Nat Commun
March 2025
Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
ER-positive/HER2-negative (ERpHER2n) breast cancer classified as PAM50 HER2-enriched (ERpHER2n-HER2E) represents a small high-risk patient subgroup. In this study, we investigate genomic, transcriptomic, and clinical features of ERpHER2n-HER2E breast tumors using two primary ERpHER2n cohorts comprising a total of 5640 patients. We show that ERpHER2n-HER2E tumors exhibit aggressive clinical features and poorer clinical outcomes compared to Luminal A and Luminal B tumors.
View Article and Find Full Text PDF